Spas Kotev, MD
Interventional Cardiology · Iowa City, IANPI 1881879971
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (56.8%), food and beverage and education — rather than concentrated in one kind of arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 12.4%. Reporting peaked in 2022 at $4,135 and has fallen 56.2% since, to $1,812 in 2025.
Across 237 payments — averaging $49.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardiovascular Systems Inc.$1K
- Inari Medical, Inc.$1K
- Boston Scientific$1K
- Abbott$1K
- W. L. Gore & Associates, Inc.$1K
- E.r. Squibb & Sons, L.L.C.$731
- plus $5K from 28 others
What the payments were for
- Travel & lodging$6,66057%
- Food & beverage$5,04543%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardiovascular Systems Inc. | 4 | $1,448 |
| Inari Medical, Inc. | 5 | $1,307 |
| Boston Scientific | 15 | $1,115 |
| Abbott | 18 | $1,108 |
| W. L. Gore & Associates, Inc. | 7 | $1,100 |
| E.r. Squibb & Sons, L.L.C. | 47 | $731 |
| Cook Incorporated | 3 | $670 |
| Stryker | 3 | $648 |
| Abiomed | 3 | $640 |
| Cook Medical LLC | 7 | $622 |
| Novartis | 28 | $465 |
| Johnson & Johnson | 19 | $319 |
| Sanofi-aventis U.S. LLC | 11 | $217 |
| Medtronic | 1 | $150 |
| Amgen | 7 | $133 |
| Philips North America LLC | 2 | $108 |
| Bayer | 5 | $106 |
| AstraZeneca | 7 | $93 |
| Regeneron Healthcare Solutions, Inc. | 4 | $83 |
| Actelion Pharmaceuticals US, Inc. | 3 | $82 |
| Boehringer Ingelheim | 5 | $76 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $71 |
| Lantheus Medical Imaging, Inc. | 4 | $71 |
| Pfizer | 4 | $55 |
| Merck | 4 | $51 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Amarin Pharma, Inc. | 3 | $42 |
| Shockwave Medical, Inc | 2 | $41 |
| Angiodynamics, Inc. | 1 | $28 |
| Itamar Medical Inc | 1 | $25 |
| Novo Nordisk | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,717 in reported general payments places this provider in the 70th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 357 | $370,253 |
| EntrestoSacubitril/Valsartan | 225 | $212,784 |
| JardianceEmpagliflozin | 218 | $163,756 |
| CamzyosMavacamten | 21 | $162,369 |
| XareltoRivaroxaban | 99 | $89,201 |
| FarxigaDapagliflozin Propanediol | 53 | $37,640 |
| BrilintaTicagrelor | 68 | $36,239 |
| Repatha SureclickEvolocumab | 26 | $18,793 |
| Praluent PenAlirocumab | 21 | $10,177 |
| Metoprolol Succinate | 796 | $9,242 |
| Ranolazine ErRanolazine | 46 | $4,347 |
| Rosuvastatin Calcium | 304 | $2,751 |
| Potassium Chloride | 121 | $2,638 |
| Flecainide Acetate | 62 | $2,526 |
| Atorvastatin Calcium | 294 | $2,273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $55 | $370,253357 claims |
| NovartisEntresto | $465 | $212,784225 claims |
| Boehringer IngelheimJardiance | $76 | $163,756218 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $731 | $162,36921 claims |
| Johnson & JohnsonXarelto | $319 | $89,20199 claims |
| AstraZenecaFarxiga, Brilinta | $93 | $73,880121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Iowa City
- Jason AllenIowa City$30K
- Hossein OuranosIowa City$28K
- Waqas SiddiquiIowa City$10K
- Hisham IbrahimIowa City$8K
- Yehia SalehIowa City$6K
- James RossenIowa City$5K
- Connor YoungIowa City$4K
- Vikram SharmaIowa City$3K
- Phillip HorwitzIowa City$3K
- Ahmad ArhamIowa City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.